Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:19:57 EST Mon 16 Feb 2026
Enter Symbol
or Name
USA
CA



News for U:BIAF from 2025-02-17 to 2026-02-16 - 54 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-02-09 08:00U:BIAFNews ReleasebioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
2026-01-07 08:00U:BIAFNews ReleasebioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
2025-12-03 08:00U:BIAFNews ReleasebioAffinity Technologies' Noninvasive CyPath(TM) Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
2025-11-14 08:00U:BIAFNews ReleasebioAffinity Technologies Reports Third Quarter 2025 Financial Results
2025-10-28 08:00U:BIAFNews ReleasebioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
2025-10-20 08:00U:BIAFNews ReleasebioAffinity Technologies Presents Research Supporting CyPath(TM) Lung Processing Methods at CHEST 2025
2025-10-16 08:00U:BIAFNews ReleasebioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
2025-10-15 08:00U:BIAFNews ReleasebioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
2025-10-09 14:00U:BIAFNews ReleaseWallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
2025-10-09 13:00U:BIAFNews ReleasebioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
2025-10-08 16:15U:BIAFNews ReleaseWallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
2025-10-08 15:45U:BIAFNews ReleasebioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
2025-10-07 08:00U:BIAFNews ReleasebioAffinity Technologies Reports Record Growth in CyPath(TM) Lung Test Volume for Third Quarter 2025
2025-09-30 12:30U:BIAFNews ReleaseWallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m
2025-09-30 12:15U:BIAFNews ReleasebioAffinity Technologies Announces Closing of $4.8 Million Public Offering
2025-09-29 17:59U:BIAFNews ReleaseWallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m
2025-09-29 15:51U:BIAFNews ReleasebioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
2025-09-26 08:00U:BIAFNews ReleasebioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath(TM) Lung
2025-09-17 08:15U:BIAFNews ReleasebioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
2025-09-09 08:00U:BIAFNews ReleaseCase Study: CyPath(TM) Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
2025-09-03 08:00U:BIAFNews ReleaseU.S. Medicine Magazine Spotlights CyPath(TM) Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
2025-08-18 08:00U:BIAFNews ReleasebioAffinity Technologies Appoints New Members to Board of Directors
2025-08-14 16:15U:BIAFNews ReleasebioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
2025-08-14 08:00U:BIAFNews ReleasebioAffinity Technologies Reports Second Quarter 2025 Results
2025-08-13 10:15U:BIAFNews ReleaseWallachBeth Capital Announces Pricing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
2025-08-13 09:25U:BIAFNews ReleasebioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
2025-08-13 08:00U:BIAFNews ReleasebioAffinity Technologies Reports Accelerating Growth in CyPath(TM) Lung Test Sales
2025-07-29 08:00U:BIAFNews ReleaseCase Study: CyPath(TM) Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
2025-07-23 08:00U:BIAFNews ReleaseCase Study: CyPath(TM) Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
2025-07-22 09:00U:BIAFNews ReleaseCanada Awards New Patent to bioAffinity Technologies for CyPath(TM) Lung, Company's Noninvasive Lung Cancer Diagnostic
2025-07-15 09:00U:BIAFNews ReleasebioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic
2025-07-09 09:00U:BIAFNews ReleaseCase Study: CyPath(TM) Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
2025-06-26 09:00U:BIAFNews ReleasebioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
2025-06-24 09:00U:BIAFNews ReleasebioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
2025-06-11 09:00U:BIAFNews ReleasebioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board
2025-06-03 09:00U:BIAFNews ReleasebioAffinity Technologies Works With Cardinal Health(TM) OptiFreight(TM) Logistics to Help Meet Demand for CyPath(TM) Lung
2025-05-28 09:00U:BIAFNews ReleasebioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
2025-05-20 09:00U:BIAFNews ReleasebioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
2025-05-15 08:30U:BIAFNews ReleasebioAffinity Technologies Reports First Quarter 2025 Results
2025-05-08 09:00U:BIAFNews ReleaseIndependent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath(TM) Lung in Diagnosing Early-Stage Lung Cancer
2025-05-07 13:15U:BIAFNews ReleaseWallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering
2025-05-07 13:00U:BIAFNews ReleasebioAffinity Technologies Announces Closing of $3.25 Million Offering
2025-05-06 10:30U:BIAFNews ReleaseWallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering
2025-05-06 09:25U:BIAFNews ReleasebioAffinity Technologies Announces Pricing of $3.25 Million Offering
2025-04-17 09:15U:BIAFNews ReleasebioAffinity Technologies Increases Efficiency of CyPath(TM) Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
2025-03-31 09:28U:BIAFNews ReleasebioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
2025-03-26 09:00U:BIAFNews ReleaseCase Study: bioAffinity Technologies' CyPath(TM) Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
2025-03-19 09:00U:BIAFNews ReleaseCase Study: bioAffinity Technologies' Positive CyPath(TM) Lung Result Leads to Detecting Breast Cancer Recurrence
2025-03-13 09:00U:BIAFNews ReleasePhysicians' Case Studies Offer Insight into Use and Benefit of CyPath(TM) Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
2025-03-06 08:00U:BIAFNews ReleasebioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath(TM) Lung Sales Growth
2025-02-26 12:10U:BIAFNews ReleaseWallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
2025-02-26 11:30U:BIAFNews ReleasebioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
2025-02-25 11:05U:BIAFNews ReleaseWallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
2025-02-25 09:58U:BIAFNews ReleasebioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million